Therapy for alcoholic liver disease
- PMID: 24605013
- PMCID: PMC3942819
- DOI: 10.3748/wjg.v20.i9.2143
Therapy for alcoholic liver disease
Abstract
Alcoholism results in about 2.5 million deaths annually worldwide, representing 4% of all mortality. Although alcoholism is associated with more than 60 diseases, most mortality from alcoholism results from alcoholic liver disease (ALD). ALD includes alcoholic steatosis, alcoholic hepatitis, and alcoholic cirrhosis, in order of increasing severity. Important scoring systems of ALD severity include: Child-Pugh, a semi-quantitative scoring system useful to roughly characterize clinical severity; model for end-stage liver disease, a quantitative, objective scoring system used for prognostication and prioritization for liver transplantation; and discriminant function, used to determine whether to administer corticosteroids for alcoholic hepatitis. Abstinence is the cornerstone of ALD therapy. Psychotherapies, including twelve-step facilitation therapy, cognitive-behavioral therapy, and motivational enhancement therapy, help support abstinence. Disulfiram decreases alcohol consumption by causing unpleasant sensations after drinking alcohol from accumulation of acetaldehyde in serum, but disulfiram can be hepatotoxic. Adjunctive pharmacotherapies to reduce alcohol consumption include naltrexone, acamprosate, and baclofen. Nutritional therapy helps reverse muscle wasting, weight loss, vitamin deficiencies, and trace element deficiencies associated with ALD. Although reduced protein intake was previously recommended for advanced ALD to prevent hepatic encephalopathy, a diet containing 1.2-1.5 g of protein/kg per day is currently recommended to prevent muscle wasting. Corticosteroids are first-line therapy for severe alcoholic hepatitis (discriminant function ≥ 32), but proof of their efficacy in decreasing mortality remains elusive. Pentoxifylline is an alternative therapy. Complications of advanced ALD include ascites, spontaneous bacterial peritonitis, esophageal variceal bleeding, hepatic encephalopathy, hepatorenal syndrome, hepatopulmonary syndrome, and portopulmonary hypertension. Alcoholic cirrhotics have increased risk of developing hepatomas. Liver transplantation is the ultimate therapy for severe ALD, but generally requires 6 mo of proven abstinence for eligibility. Alcoholic cirrhotics who maintain abstinence generally have a relatively favorable prognosis after liver transplantation.
Keywords: Alcoholic cirrhosis; Alcoholic hepatitis; Alcoholic liver disease; Alcoholic steatosis; Alcoholism; Corticosteroids; Liver disease; Liver transplantation; Pentoxifylline.
Figures

Similar articles
-
Liver transplantation and alcoholic liver disease: History, controversies, and considerations.World J Gastroenterol. 2018 Jul 14;24(26):2785-2805. doi: 10.3748/wjg.v24.i26.2785. World J Gastroenterol. 2018. PMID: 30018475 Free PMC article. Review.
-
Pharmacotherapy of alcoholic liver disease in clinical practice.Int J Clin Pract. 2016 Feb;70(2):119-31. doi: 10.1111/ijcp.12764. Epub 2015 Dec 28. Int J Clin Pract. 2016. PMID: 26709723 Review.
-
Current Status of Alcoholic Liver Disease in Japan and Therapeutic Strategy.Nihon Arukoru Yakubutsu Igakkai Zasshi. 2016 Aug;51(2):71-90. Nihon Arukoru Yakubutsu Igakkai Zasshi. 2016. PMID: 30462383 Review.
-
Diagnosis and management of alcoholic liver disease.J Dig Dis. 2011 Aug;12(4):257-62. doi: 10.1111/j.1751-2980.2010.00470.x. J Dig Dis. 2011. PMID: 21091932 Review.
-
Pharmacotherapy for alcoholic patients with alcoholic liver disease.Am J Health Syst Pharm. 2014 Aug 1;71(15):1265-76. doi: 10.2146/ajhp140028. Am J Health Syst Pharm. 2014. PMID: 25027533 Free PMC article. Review.
Cited by
-
Chronic Alcoholic Liver Disease and Mortality Risk in Spontaneous Bacterial Peritonitis: Analysis of 6,530 Hospitalizations.Cureus. 2020 May 18;12(5):e8189. doi: 10.7759/cureus.8189. Cureus. 2020. PMID: 32566430 Free PMC article.
-
The management of alcohol use disorders: the impact of pharmacologic, affective, behavioral, and cognitive approaches.Prim Care Companion CNS Disord. 2014 Aug 21;16(4):10.4088/PCC.14f01683. doi: 10.4088/PCC.14f01683. eCollection 2014. Prim Care Companion CNS Disord. 2014. PMID: 25664205 Free PMC article. No abstract available.
-
Molecular, Viral and Clinical Features of Alcohol- and Non-Alcohol-Induced Liver Injury.Curr Issues Mol Biol. 2022 Mar 16;44(3):1294-1315. doi: 10.3390/cimb44030087. Curr Issues Mol Biol. 2022. PMID: 35723310 Free PMC article. Review.
-
Natural Compounds: A Potential Treatment for Alcoholic Liver Disease?Front Pharmacol. 2021 Jul 5;12:694475. doi: 10.3389/fphar.2021.694475. eCollection 2021. Front Pharmacol. 2021. PMID: 34290612 Free PMC article. Review.
-
Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease.Cochrane Database Syst Rev. 2016 Mar 2;3(3):CD011602. doi: 10.1002/14651858.CD011602.pub2. Cochrane Database Syst Rev. 2016. PMID: 26934429 Free PMC article.
References
-
- World Health Organization. Global status report on alcohol and health. Geneva: World Health Organization; 2011. p. 286.
-
- Kim WR, Brown RS, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology. 2002;36:227–242. - PubMed
-
- American Psychiatric Association. Alcohol Use Disorder. Diagnostic and Statistical Manual of Mental Disorders. Arlington, VA: American Psychiatric Publishing; 2013. pp. 490–497.
-
- National Institute on Alcohol Abuse and Alcoholism. Rethinking Drinking: Alcohol and Your Health, 2010. Available from: http://rethinkingdrinking.niaaa.nih.gov.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases